the shift of the balance between txa2 and pgi2 to the dominance of antiaggregatory pgi2 during sulphinpyrazone treatment may be involved with the efficacy of the drug in the secondary prevention of myocardial infarction .
C0038742
sulphinpyrazone
C0027051
myocardial infarction